tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
REGN is currently covered by 22 analysts with an average price target of $865.13. This is a potential upside of $123.21 (16.61%) from yesterday's end of day stock price of $741.92.
Regeneron Pharmaceuticals's activity chart (see below) currently has 851 price targets and 677 ratings on display. The stock rating distribution of REGN is 69.33% BUY, 26.67% HOLD and 4% SELL.
Analysts average stock forecasts to be materialized ratio is 87.8% with an average time for these price targets to be met of 264.17 days.
Highest price target for REGN is $1057, Lowest price target is $587, average price target is $802.9.
Most recent stock forecast was given by TIM ANDERSON from BAML on 07-Jan-2026. First documented stock forecast 30-Sep-2013.
Regeneron Pharmaceuticals specializes in products that enable minimally invasive care.
The da Vinci Surgical System is a robotic surgical system that includes:
The surgeon uses the console to control the instruments, which are inserted into the patient’s body through small incisions. The system allows for greater precision and control during surgery, resulting in reduced trauma to the patient and faster recovery times.
The Ion endoluminal system enables minimally invasive biopsies in the lung, which can help diagnose lung cancer and other conditions.
Intuitive Surgical also provides a suite of stapling, energy, and core instrumentation for its surgical systems, as well as progressive learning pathways to support the use of its technology. The company offers a complement of services to its customers, including support, installation, repair, and maintenance, to ensure that its products operate efficiently and effectively.
Moreover, Intuitive Surgical has integrated digital capabilities providing connected offerings that streamline performance for hospitals with program-enhancing insights.
The company was founded in 1995 and is headquartered in Sunnyvale, California.
Currently out of the existing stock ratings of REGN, 52 are a BUY (69.33%), 20 are a HOLD (26.67%), 3 are a SELL (4%).
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell
Since 10-Dec-2024
$860
$63.45 (7.97%)
$627
8 days ago
(07-Jan-2026)
3/5 (60%)
$83.46 (10.75%)
157
Hold
Since 12-Dec-2025
$768
$-28.55 (-3.58%)
$767
1 months 3 days ago
(12-Dec-2025)
44/50 (88%)
$21.2 (2.84%)
215
Hold
Since 30-May-2025
$745
$-51.55 (-6.47%)
$700
1 months 5 days ago
(10-Dec-2025)
17/21 (80.95%)
$18.79 (2.59%)
141
Buy
Since 03-Nov-2023
$1057
$260.45 (32.70%)
$850
1 months 11 days ago
(04-Dec-2025)
21/25 (84%)
$315 (42.45%)
311
Buy
Since 06-May-2020
$767
$-29.55 (-3.71%)
1 months 11 days ago
(04-Dec-2025)
5/5 (100%)
$25 (3.37%)
463
What is REGN (Regeneron Pharmaceuticals) average time for price targets to be met?
Which analyst has the current highest performing score on REGN (Regeneron Pharmaceuticals) with a proven track record?
Which analyst has the most public recommendations on REGN (Regeneron Pharmaceuticals)?
Which analyst is the currently most bullish on REGN (Regeneron Pharmaceuticals)?
Which analyst is the currently most reserved on REGN (Regeneron Pharmaceuticals)?
